When did LivaNova go public?
LivaNova PLC officially became a publicly traded medical technology enterprise following the completion of a landmark cross-border corporate merger between Cyberonics and Sorin Group. The newly combined entity commenced trading its ordinary shares on the NASDAQ global select market under the ticker symbol LIVN in October 2015. The strategic merger united neuromodulation and cardiac surgery technologies, establishing a global medical device company specializing in cardiovascular and neurostimulation therapies.
Related FAQs
LivaNova maintains its official corporate incorporation and global executive headquarters in London, United Kingdom.
Companies that operate similarly to LivaNova within the medical technology and neuromodulation space include specialized cardiovascular and neurological device manufacturers such as Medtronic, Boston Scientific, Abbott Laboratories, and Edwards Lifes...
LivaNova, a prominent multinational medical device and technology company, faced a wave of class action lawsuits and public scrutiny following a major cybersecurity incident and data breach.
LivaNova PLC trades on the Nasdaq stock exchange under the ticker symbol LIVN at approximately $80.14 per share.
Equity research analysts evaluate LivaNova PLC (LIVN) with favorable long-term growth prospects, supported by its medical technology innovations centered on neuromodulation and cardiovascular systems.
LivaNova PLC, a global medical technology enterprise specializing in the design, development, and distribution of cardiovascular and neuromodulation therapy systems—including advanced vagus nerve stimulation devices and cardiac surgery equipment—has ...
LivaNova PLC is an authentic, highly respected, and fully legitimate global medical technology enterprise that develops, manufactures, and markets innovative cardiovascular and neuromodulation devices.
Equity research analysts covering LivaNova, trading under the ticker symbol LIVN, generally maintain balanced consensus recommendations leaning toward moderate buy or hold ratings.
LivaNova PLC is a global medical technology company that designs, develops, and markets innovative medical devices for cardiovascular and neuromodulation therapies.
Employee reviews for LivaNova generally reflect a mission-driven, highly collaborative corporate culture centered on developing advanced medical technologies for neuromodulation and cardiovascular care.
Yes, Cyberonics is no longer an independent entity; it is now part of LivaNova PLC. LivaNova was formed in 2015 through the merger of Cyberonics and the Italian medical technology firm Sorin.
LivaNova PLC, a global medical technology company headquartered in London, has reported consistent annual revenue growth reflecting the success of its specialized product lines in cardiac surgery and neuromodulation.
LivaNova’s total revenue is primarily derived from its two main business segments: Cardiopulmonary and Neuromodulation.
Sorin Group is officially part of LivaNova PLC, having completed a massive, high-profile cross-border business combination with United States-based medical device maker Cyberonics.
LivaNova operates as a fully public enterprise, with its common shares listed and actively traded on the NASDAQ stock exchange under the ticker symbol LIVN.
Live Oak Bank structures its digital business and personal savings accounts to eliminate standard monthly maintenance fees, allowing account holders to grow their deposits without seeing balances eroded by everyday administrative banking charges.
LivaNova PLC is a global medical technology enterprise that designs, develops, and manufactures specialized cardiovascular and neuromodulation medical devices.
LivaNova is not strictly a domestic United States corporation, functioning instead as an international public enterprise legally incorporated and headquartered in London, United Kingdom.
Live Oak Bank has been operating as a specialized commercial and digital-first financial institution for over two decades, having been officially founded in the year 2008 by industry veterans James S. Mahan III and Paul Parker.
LivaNova PLC is a global medical technology corporation headquartered in London, United Kingdom, dedicated to developing and delivering transformative cardiovascular and neuromodulation solutions for healthcare professionals worldwide.
Evaluating LivaNova as a long-term investment involves analyzing its market positioning in specialized medical device niches, ongoing clinical trial pipelines, and regulatory approval milestones.
LS Power maintains a dedicated and highly specialized workforce of approximately 800 to 1,000 employees.